Knopp Biosciences to Present at Piper Jaffray 31st Annual Healthcare Conference
12.11.2019 14:00:00 EET | Business Wire | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York, NY on December 3-5.
Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, December 3rd at 8:10 a.m. Eastern Time.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy, non-opioid treatments for pain, and other CNS hyperexcitability disorders. Please visit www.knoppbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191112005219/en/
Contact information
Media inquiries:
Westwicke PR
Media:
Kate Coyle
Kate.Coyle@icrinc.com
203-682-8210
Surabhi Verma
Surabhi.Verma@icrinc.com
646-677-1825
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Announces Armis Centrix™ for Vulnerability Management Detection and Response to Reduce Cyber Risk and Eliminate Operational Friction10.3.2026 14:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced Armis Centrix™ for Vulnerability Management Detection and Response. The solution enables security teams to precisely identify and validate vulnerabilities across all of an organization’s assets in real time. Armis’ unified approach to vulnerability assessment results in greater accuracy, faster detection time and reduced operational costs. "Waiting weeks for a vulnerability scan that still misses essential assets is no longer sufficient to combat AI-powered cyberattacks,” said Nadir Izrael, CTO and Co-Founder at Armis. “Organizations need a continuous view of their complete environment to stay ahead of threats. Armis' new solution delivers more accurate, targeted results than traditional vulnerability management solutions with a fraction of the scans. It empowers security teams to shift from a reactive approach that relies on stale data to targeted, real-time vulnerability detection, allowing them to save time, en
Wolters Kluwer Releases 2026 Future Ready Lawyer Survey Report, Highlighting Rapid AI Gains and Shifting Power Dynamics10.3.2026 14:00:00 EET | Press release
Wolters Kluwer Legal & Regulatory has published the results of its global 2026 Future Ready Lawyer Survey, the preeminent source of insights from lawyers in law firms and corporate legal departments across the U.S., China and nine European countries. The findings show an industry coming to grips with the accelerated adoption of AI technology, an ambitious undertaking that has yielded long sought-after efficiencies across workflows and business practices, while raising unexpected challenges to ethics and infrastructure. “The Future Ready Lawyer global report has always reflected an industry in motion,” said Martin O'Malley, CEO of Wolters Kluwer Legal & Regulatory. “What’s most striking this year is how rapidly legal professionals are accelerating to meet that change by reshaping business models, rethinking long‑held dynamics, and embracing new ways to deliver value through both evolving skills and bold technology.” AI Delivers, Challenges Persist A substantial majority of respondents (
Nexpring Health Invests in May Health to Advance a Novel Technology to Treat PCOS-Related Infertility10.3.2026 14:00:00 EET | Press release
Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, today announced a strategic investment in May Health, a medical device company pioneering a novel treatment approach for women with polycystic ovary syndrome (PCOS)-related infertility. Nexpring Health joined May Health’s €10 million ($11.7M) financing round alongside investors including Sofinnova Partners, Trill Impact, and Bpifrance. This investment reflects Nexpring Health's commitment to driving meaningful innovation that moves the field of fertility care forward and goes beyond the products in the lab by supporting the innovations that redefine what’s possible for patients and the clinicians who serve them. Backing the Breakthrough That PCOS Patients Need PCOS is the most common endocrine condition among reproductive-aged women and a leading cause of female infertility, affecting an estimated 10–13% of women worldwide. 1,2 Women with PCOS-related infertility often struggle to become pregnant beca
United UATP, Powered by TreviPay, Expands Corporate Travel Billing Program to New Global Markets10.3.2026 14:00:00 EET | Press release
UATP, the global network that enables organizations to simplify payment processes and expand their payment capabilities, today announced the expansion of United Airlines’ cost-free UATP billing program (“United UATP”), powered by TreviPay, to Europe, Australia and New Zealand. This expansion opens new opportunities for corporate customers and travel agencies in these regions to access the benefits of United UATP, including cost-free, streamlined travel expense reconciliation. Since 2015, United UATP has collaborated with TreviPay, a fully managed B2B payments platform, to power its streamlined solution for air travel payments in the U.S. and Canada. For companies currently benefitting from the United UATP billing program, TreviPay handles customer service, underwriting risk, and manages the processing, invoicing in local currencies, and accounts receivable automation, including disputes, collections and reconciliation. A consolidated invoice process provides streamlined access to Level
Perion's AI Agent Outmax Now Available for TikTok, Delivering Up to 25% Greater Media Performance in Early Results10.3.2026 13:00:00 EET | Press release
Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced the launch of its proprietary Outmax AI agent for TikTok. This integration extends Perion’s capabilities to one of the fastest-growing global advertising platforms, with nearly 1.6 billion users worldwide and rapidly expanding advertiser adoption as brands increasingly prioritize TikTok in their media strategies. TikTok’s advertising revenue is expected to exceed $50 billion by 20271. Perion’s Outmax AI agent is embedded within Perion’s AI-native infrastructure, designed to increase advertiser efficiency and performance. Fully integrated with TikTok, Outmax applies algorithmic intelligence beyond native platform defaults, enabling advertisers to optimize against brand-defined business outcomes rather than platform-standard KPIs. The new Outmax for TikTok AI Model is already delivering up to 25% better
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom